Group 1 - The core viewpoint of the article indicates that Dachen Biochemical Technology (00809.HK) expects a significant decline in net profit for the fiscal year ending December 31, 2025, projecting a range of HKD 100 million to HKD 300 million, which is substantially lower than the approximately HKD 746 million net profit recorded for the fiscal year ending December 31, 2024 [1] Group 2 - The company has conducted a preliminary review of its unaudited consolidated management accounts for the upcoming fiscal year [1] - The expected net profit for the upcoming fiscal year represents a decrease of approximately 60% to 87% compared to the previous year's figures [1] - The announcement highlights a concerning trend in the company's financial performance, indicating potential challenges ahead [1]
大成生化科技(00809.HK)：预计2025年度净收益1亿港元至3亿港元